

Report Information

More information from: <https://www.marketresearchfuture.com/reports/anxiety-disorder-treatment-market-8455>

Anxiety Disorder Treatment Market Research Report - Global Forecast till 2030

Report / Search Code: MRFR/HC/6983-HCR

Publish Date: July, 2023

[Request Sample](#)

Price	1-user PDF : \$ 4950.0	Site PDF : \$ 3250.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------	----------------------------

Description:

Anxiety Disorder Treatment Market Overview

The Anxiety Disorder Treatment Market is projected to reach USD 9 Billion by 2030 at 2.90% CAGR during the forecast period 2022-2030. Anxiety disorders account for a 8.60% share of the global disease burden. It includes panic disorders, post-traumatic stress disorder (PTSD), phobias, and obsessive-compulsive disorder. Anxiety disorders correspond with a high burden of illness as they are psychiatric disorders. Owing to increasing cases of anxiety disorders there is a need for the development of ingenious drugs for effective treatment. Additionally, various reimbursement policies present in developed countries for therapies and medication influences the market positively.

COVID 19 Analysis

The global pandemic of COVID 19 has affected a large section of society. Most of the people who had got Corona Virus is struggling with anxiety disorders. Owing to the increasing cases of generalized anxiety disorders, huge investments have been made by manufacturers for the development of anxiety disorder treatment. There are various types of anxiety disorders like agoraphobia, generalized anxiety disorder, and social anxiety disorder. This investment gives rise to increasing medication and hence increases the anxiety disorder treatment market size in the global market.

The global pandemic of COVID 19 has a positive effect on the global market share of this drug. The market share for this treatment is also expected to grow furthermore in the coming years.

Market Dynamics

• Drivers

The rising number of anxiety disorders such as agoraphobia, generalized anxiety disorder, social anxiety disorder, and many others. This anxiety problem is most commonly prevailing in the US, affecting almost 40 million people who are above the age of 18 which increases the demand for effective treatment for these anxiety disorders. Also, the presence of reimbursement policies in various developed countries is another driving factor.

• Opportunities

An increasing number geriatric population coupled with changing lifestyles are the main growth opportunities for the anxiety disorder treatment market. In the US major chunk of the population is aged above 65. It was found in studies that the chances of mental illness increase with the increase in age of an individual. They are more prone to psychological disorders. Also, the increasing advancement in technology is another growth opportunity.

• Restraints

The anxiety disorder treatment market is flourishing all across the globe but some factor restricts its growth. One of the factors that hamper the market growth is the expiration of patents on branded medicines. Another factor is the presence of generic biosimilars which is a cost-effective alternative present introduced by various critical players. Biosimilars have reached the end of proprietary patents as it is a similar version of approved biologics which hampers the growth in the global market.

Value Chain Analysis

The anxiety disorder treatment market is growing rapidly in the global market owing to various benefits provided by it. It helps in providing relief during the pain caused by anxiety disorders. Also, different drugs class helps in treating different types of anxiety disorder problems. The Buspirone drug helps in treating generalized anxiety disorder. Moclobemide helps in treating anxiety disorders. Tricyclic Antidepressant affects brain chemicals for reducing symptoms of depression.

Anxiety Disorder Treatment Market Segmentation

The anxiety disorder treatment market has been divided all across the globe based on drug class and end-users.

Based on the Drug Class

The anxiety disorder treatment market has been divided all across the globe based on the drug class into moclobemide (helps in treating social anxiety and depression. This medicine is largely used in Western Europe especially in Australia, UK, and Canada. Though this medicine is not approved in the US), benzodiazepines (helps in treating anxiety), buspirone (helps in treating generalized anxiety disorder. This medicine is also known as anxiolytics), pregabalin (helps in treating epilepsy and generalized anxiety disorder. This medicine gives relief by sending pain signals towards the nervous system), Tricyclic Antidepressants (TCAs) (helps to ease depression symptoms by affecting brain chemicals), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) (helps in reducing symptoms of depression symptoms, nerve pain, and anxiety disorders like sadness and irritability), and Selective Serotonin Reuptake Inhibitors (SSRIs) (these are commonly used as antidepressants for treating depressive disorders and anxiety disorders by blocking the reabsorption of serotonin in the brain. This treatment drug also has little side-effects).

Based on the End-Users

The anxiety disorder treatment market has been divided all across the globe based on the end-users into asylums (special institutions created for the special purpose of providing housing facilities for psychologically disorder people), mental healthcare centers (they provide a primary line of treatment and it is the most extensive care), hospitals, and many others. The largest market share is held by the hospital dividend owing to the increasing financing capabilities of the healthcare sector coupled with an increasing number of patients. The government of different regions is investing huge sums in improving the healthcare sector).

Anxiety Disorder Treatment Market Regional Analysis

The anxiety disorder treatment market has been divided all across the globe based on the region into the American region, European region, Asia-Pacific region, and the Middle East and African region. The largest market share is held by the American region owing to the increase in the number of anxiety disorder patients. The number of cases in the American region is increasing due to the stressful work environment and sedentary lifestyle.

The second-largest anxiety disorder treatment market share all across the globe is held by the European region owing to increasing awareness regarding the anxiety disorder problem and the availability of its effective treatment.

The third-largest anxiety disorder treatment market share all across the globe is held by the Asia-Pacific region owing to increasing generalized anxiety disorders coupled with psychological diseases which increases the demand for anxiety disorder treatment.

The Middle East and African region show a steady growth rate owing to small market size coupled with a lack of awareness regarding the availability of effective treatments for anxiety disorders in this region.

Anxiety Disorder Treatment Market Competitive Landscape

The most prominent major key players in the anxiety disorder treatment market all across the globe are mentioned below:

- Bristol-Myers Squibb Company (US)
- Lundbeck A/S (Denmark)
- Johnson and Johnson (US)
- GlaxoSmithKline PLC (UK)
- Pfizer
- Merck & Co.
- Sanofi-Aventis (France)
- AstraZeneca PLC (UK)
- Forest Laboratories
- Eli Lilly and Company (US)

These major key players use various strategies to sustain their market position in the anxiety disorder treatment market in the global market by going for mergers, and acquisitions, by collaborating, setting up a new joint venture, establishing a partnership, developing a new production process, developing a new product line, innovation in the existing product, and many others to expand their customer base in the untapped market of the anxiety disorder treatment all across the globe.

Recent Developments

- In December 2020, Cadent Therapeutics had been acquired by Novartis for a consideration of USD 770 million. It will help Novartis to broaden its presence in the mental health area by leveraging Cadent's neuroscience portfolio.
- In December 2020, NeuroRx merged with big rock partners acquisition corporation for developing therapies for COVID 19 and bipolar disorder. The combined value of the company will be around USD 500 million.
- In August 2020, a new drug application (NDA) of esketamine has been approved by US FDA for treating depressive disorder (MDD).
- In March 2020, results of the STRIDE-1 Phase 3 trial were disclosed significantly by Axsome Therapeutics Inc. for the treatment of resistant depression.

Anxiety Disorder Treatment Market Report Overview

This global anxiety disorder treatment market research report consists of the following elements mentioned below:

- Market Overview
- COVID 19 Analysis
- Market Dynamics
- Value Chain Analysis
- Market Segmentation
- Regional Analysis
- Competitive Landscape
- Recent Developments

This market research report contains factors that drive the growth of the anxiety disorder treatment market in the global market along with the factors that restrict its growth in the global market. The opportunities available for growth during the forecasted period are mentioned. The impact of COVID 19 on the sales revenue of the anxiety disorder treatment market all across the globe is mentioned. The future growth rate during the forecasted period is estimated and mentioned.

Intended Audience

Anxiety disorder drugs manufacturing companies, research and development (R & D) companies, government organizations, healthcare organizations, healthcare providers, and many others.

Table of Content:

Contents
Table of Contents

1. REPORT PROLOGUE	
2. MARKET INTRODUCTION	
2.1. Definition	
2.2. Scope of the Study	
2.2.1. Research Objective	
2.2.2. Assumptions	
2.2.3. Limitations	
3. RESEARCH METHODOLOGY	
3.1. Overview	
3.2. Primary Research	
3.3. Secondary Research	
3.4. Market Size Estimation	
4. MARKET DYNAMICS	
4.1. Overview	
4.2. Drivers	
4.3. Restraints	
4.4. Opportunities	
5. MARKET FACTOR ANALYSIS	
5.1. Porter's Five Forces Analysis	
5.1.1. Bargaining Power of Suppliers	
5.1.2. Bargaining Power of Buyers	
5.1.3. Threat of New Entrants	
5.1.4. Threat of Substitutes	
5.1.5. Intensity of Rivalry	
5.2. Value Chain Analysis	
6. GLOBAL ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS	
6.1. Overview	
6.2. SSRIs (Selective Serotonin Reuptake Inhibitors)	
Market Estimates & Forecast, by Region, 2020-2027	
Market Estimates & Forecast, by Country, 2020-2027	
6.3. SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)	
Market Estimates & Forecast, by Region, 2020-2027	
Market Estimates & Forecast, by Country, 2020-2027	
6.4. TCAs (Tricyclic Antidepressants)	
Market Estimates & Forecast, by Region, 2020-2027	
Market Estimates & Forecast, by Country, 2020-2027	
6.5. Pregabalin	
Market Estimates & Forecast, by Region, 2020-2027	
Market Estimates & Forecast, by Country, 2020-2027	
6.6. Buspirone	
Market Estimates & Forecast, by Region, 2020-2027	
Market Estimates & Forecast, by Country, 2020-2027	
6.7. Benzodiazepines	
Market Estimates & Forecast, by Region, 2020-2027	
Market Estimates & Forecast, by Country, 2020-2027	
6.8. Moclobemide	
Market Estimates & Forecast, by Region, 2020-2027	
Market Estimates & Forecast, by Country, 2020-2027	
6.9. Others	
Market Estimates & Forecast, by Region, 2020-2027	
Market Estimates & Forecast, by Country, 2020-2027	
7. GLOBAL ANXIETY DISORDER TREATMENT MARKET, BY END USER	
7.1. Overview	
7.2. Hospitals	
Market Estimates & Forecast, by Region, 2020-2027	

Market Estimates & Forecast, by Country, 2020-2027
7.3. Mental Healthcare Centers
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Asylums
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL ANXIETY DISORDER TREATMENT MARKET, BY REGION

8.1. Overview
8.2. Americas
8.2.1. North America
8.2.1.1. US
8.2.1.2. Canada
8.2.2. Latin America
8.3. Europe
8.3.1. Western Europe
8.3.1.1. Germany
8.3.1.2. France
8.3.1.3. Italy
8.3.1.4. Spain
8.3.1.5. UK
8.3.1.6. Rest of Western Europe
8.3.2. Eastern Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle East & Africa
8.5.1. Middle East
8.5.2. Africa
9. COMPANY LANDSCAPE
9.1.1. Overview
9.1.2. Competitive Analysis
10. COMPANY PROFILES
10.1. Eli Lilly and Company
10.1.1. Company Overview
10.1.2. Product Type Overview
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Forest Laboratories, Inc.
10.2.1. Company Overview
10.2.2. Product Type Overview
10.2.3. Financial Overview
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. AstraZeneca PLC
10.3.1. Company Overview
10.3.2. Product Type Overview
10.3.3. Financial Overview
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Sanofi-Aventis
10.4.1. Company Overview
10.4.2. Product Type Overview
10.4.3. Financial Overview
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Merck & Co., Inc.
10.5.1. Company Overview
10.5.2. Product Type Overview
10.5.3. Financial Overview
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Pfizer, Inc.
10.6.1. Company Overview
10.6.2. Product Type Overview
10.6.3. Financial Overview
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. GlaxoSmithKline PLC
10.7.1. Company Overview
10.7.2. Product Type Overview
10.7.3. Financial Overview
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Johnson & Johnson
10.8.1. Company Overview
10.8.2. Product Type Overview

10.8.3. Financial Overview
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Lundbeck A/S
10.9.1. Company Overview
10.9.2. Product Type Overview
10.9.3. Financial Overview
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Bristol-Myers Squibb Company
10.10.1. Company Overview
10.10.2. Product Type Overview
10.10.3. Financial Overview
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. Others
11. APPENDIX
11.1. References
11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL ANXIETY DISORDER TREATMENT MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL ANXIETY DISORDER TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL ANXIETY DISORDER TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL ANXIETY DISORDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 6 NORTH AMERICA: ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 7 NORTH AMERICA: ANXIETY DISORDER TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 8 US: ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 9 US: ANXIETY DISORDER TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 10 CANADA: ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 11 CANADA: ANXIETY DISORDER TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 12 LATIN AMERICA: ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 13 LATIN AMERICA: ANXIETY DISORDER TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 14 EUROPE: ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 15 EUROPE: ANXIETY DISORDER TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 16 WESTERN EUROPE: ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 17 WESTERN EUROPE: ANXIETY DISORDER TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 18 EASTERN EUROPE: ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 19 EASTERN EUROPE: ANXIETY DISORDER TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC: ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 21 ASIA-PACIFIC: ANXIETY DISORDER TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA: ANXIETY DISORDER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA: ANXIETY DISORDER TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ANXIETY DISORDER TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ANXIETY DISORDER TREATMENT MARKET
FIGURE 4 GLOBAL ANXIETY DISORDER TREATMENT MARKET SHARE, BY DRUG CLASS, 2018 (%)
FIGURE 5 GLOBAL ANXIETY DISORDER TREATMENT MARKET SHARE, BY END USER, 2018 (%)
FIGURE 6 GLOBAL ANXIETY DISORDER TREATMENT MARKET SHARE, BY REGION, 2018 (%)
FIGURE 7 AMERICAS: ANXIETY DISORDER TREATMENT MARKET SHARE BY REGION, 2018 (%)
FIGURE 8 EUROPE: ANXIETY DISORDER TREATMENT MARKET SHARE, BY REGION, 2018 (%)
FIGURE 9 WESTERN EUROPE: ANXIETY DISORDER TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 10 ASIA-PACIFIC: ANXIETY DISORDER TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 11 MIDDLE EAST & AFRICA: ANXIETY DISORDER TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 12 GLOBAL ANXIETY DISORDER TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2018 (%)
FIGURE 13 ELI LILLY AND COMPANY: KEY FINANCIALS
FIGURE 14 ELI LILLY AND COMPANY: SEGMENTAL REVENUE
FIGURE 15 ELI LILLY AND COMPANY: REGIONAL REVENUE
FIGURE 16 FOREST LABORATORIES, INC.: KEY FINANCIALS
FIGURE 17 FOREST LABORATORIES, INC.: SEGMENTAL REVENUE
FIGURE 18 FOREST LABORATORIES, INC.: REGIONAL REVENUE
FIGURE 19 ASTRAZENECA PLC: KEY FINANCIALS
FIGURE 20 ASTRAZENECA PLC: SEGMENTAL REVENUES
FIGURE 21 ASTRAZENECA PLC: REGIONAL REVENUE
FIGURE 22 SANOFI-AVENTIS: KEY FINANCIALS
FIGURE 23 SANOFI-AVENTIS: SEGMENTAL REVENUE
FIGURE 24 SANOFI-AVENTIS: REGIONAL REVENUE
FIGURE 25 MERCK & CO., INC.: KEY FINANCIALS
FIGURE 26 MERCK & CO., INC.: SEGMENTAL REVENUE
FIGURE 27 MERCK & CO., INC.: REGIONAL REVENUE
FIGURE 28 PFIZER, INC.: KEY FINANCIALS
FIGURE 29 PFIZER, INC.: SEGMENTAL REVENUE

FIGURE 30 PFIZER, INC.: REGIONAL REVENUE
FIGURE 31 GLAXOSMITHKLINE PLC: KEY FINANCIALS
FIGURE 32 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE
FIGURE 33 GLAXOSMITHKLINE PLC: REGIONAL REVENUE
FIGURE 34 JOHNSON & JOHNSON: KEY FINANCIALS
FIGURE 35 JOHNSON & JOHNSON: SEGMENTAL REVENUE
FIGURE 36 JOHNSON & JOHNSON: REGIONAL REVENUE
FIGURE 37 LUNDBECK A/S: KEY FINANCIALS
FIGURE 38 LUNDBECK A/S SEGMENTAL REVENUE
FIGURE 39 LUNDBECK A/S: REGIONAL REVENUE
FIGURE 40 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS
FIGURE 41 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE
FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE